Alternating Bi-Weekly Intravitreal Ranibizumab and Bevacizumab for Refractory Neovascular Age-Related Macular Degeneration with Pigment Epithelial Detachment^*

References

• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1419–1431
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1432–1444
   PubMed Web of Science ®Google Scholar
• Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119(7):1388–1398
   PubMed Web of Science ®Google Scholar
• Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmology 2007;143(4):566–583
   PubMed Web of Science ®Google Scholar
• Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148(1):43–58
   PubMed Web of Science ®Google Scholar
• Gupta OP, Shienbaum G, Patel AH, et al. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology 2010;117(11):2134–2140
   PubMed Web of Science ®Google Scholar
• Golbaz I, Ahlers C, Stock G, et al. Quantification of the therapeutic response of intraretinal, subretinal and subpigment epithelial compartments in exudative AMD during anti-VEGF therapy. Invest Ophthalmol Vis Sci 2011;52(3):1599–1605
   PubMed Web of Science ®Google Scholar
• Ritter M, Bolz M, Sacu S, et al. Effect of intravitreal ranibizumab in avascular pigment epithelial detachment. Eye 2010;24(6):962–968
   PubMed Web of Science ®Google Scholar
• Chen E, Kaiser RS, Vander JF. Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration. Retina 2007;27:445–450
   PubMed Web of Science ®Google Scholar
• Arora S, McKibbin M. One-year outcome after intravitreal ranibizumab for large, serous pigment epithelial detachment secondary to age-related macular degeneration. Eye 2011;25:1034–1038
   PubMed Web of Science ®Google Scholar
• Freeman WR, Kozak I, Yuson RM, et al. Prognostic implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization. Retina 2011;31(9):1812–1818
   PubMed Web of Science ®Google Scholar
• Garg SJ, Brod R, Kim D, et al. Tears of the retinal pigment epithelium after intravitreal injection of bevacizumab for exudative age-related macular degeneration. Clin Exp Ophth 2008;36(3):252–256
   PubMed Web of Science ®Google Scholar
• Gasperini JL, Fawzi AA, Khondkaryan A, et al. Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol 2012;96(1):14–20
   PubMed Web of Science ®Google Scholar
• Forooghian F, Cukras C, Meyerle CB, et al. Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina 2009;29(6):723–731
   PubMed Web of Science ®Google Scholar
• Hau VS. VEGF trap-eye (aflibercept) effectiveness in wet AMD patients recalcitrant to ranibizumab and bevacizumab. August 25--29, 2012; ASRS Annual Meeting, Las Vegas, NV
   Google Scholar
• Shah CP, Cho H, Cleary TS, et al. Aflibercept for exudative AMD suboptimally responsive to ranibizumab and bevacizumab. August 25--29, 2012; ASRS Annual Meeting, Las Vegas, NV
   Google Scholar
• Kaiser PK, Boyer DS, Cruess AF, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. Ophthalmology 2012;119(5):1001–1010
   PubMed Web of Science ®Google Scholar
• Singh CN, Saperstein DA. Combination treatment with reduced-fluence photodynamic therapy and intravitreal injection of triamcinolone for subfoveal choroidal neovascularization in macular degeneration. Retina 2008;28(6):789–793
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Brown DM, Chen E, et al. SAVE Study Group. SAVE (Super-dose Anti-VEGF) Trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results. Ophthalmic Surg Lasers Imaging Retina 2013;44(2):121–126
   PubMed Web of Science ®Google Scholar
• Fung AT, Kumar N, Vance SK, et al. Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study). Eye 2012;26(9):1181–1187
   PubMed Web of Science ®Google Scholar
• Stewart MW, Rosenfeld PJ, Penha FM, et al. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor trap-eye). Retina 2012;32(3):434–457
   PubMed Web of Science ®Google Scholar
• Schaal S, Kaplan HJ, Tezel TH. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology 2008;115(12):2199–2205
   PubMed Web of Science ®Google Scholar
• Eghøj MS, Sørensen TL. Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 2012;96(1):21–23
   PubMed Web of Science ®Google Scholar
• Curtis LH, Hammill BG, Schulman KA, Cousins SW. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 2010;128(10):1273–1279
   PubMed Web of Science ®Google Scholar
• Ladas ID, Karagiannis DA, Rouvas AA, et al. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections. Retina 2009;29(3):313–318
   PubMed Web of Science ®Google Scholar